Messenger RNA editing of the human serotonin 5-HT2creceptor

Neuropsychopharmacology

Volumn 21, Issue , 1999, Pages 82S-90S

  Fitzgerald, Lawrence W ^a   Iyer, Geeta ^a   Conklin, Deborah S ^a   Krause, Carol M ^a   Marshall, Anne ^a   Patterson, John P ^a   Tran, David P ^a   Jonak, Gerald J ^a   Hartig, Paul R ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Efficacy; Intrinsicactivity; LSD; MCPP; RNA editing; Serotonin receptor; Transcriptional modification

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ADENOSINE; CLOZAPINE; COMPLEMENTARY DNA; FLUOXETINE; GUANINE NUCLEOTIDE BINDING PROTEIN; KETANSERIN; LISURIDE; LYSERGIDE; MESSENGER RNA; MESULERGINE; MIANSERIN; OXYMETAZOLINE; PHOSPHATIDYLINOSITIDE; RECOMBINANT RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SPIPERONE;

ARTICLE; BINDING AFFINITY; BRAIN; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; HYPOTHALAMUS; LIGAND BINDING; NUCLEOTIDE SEQUENCE; PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; RNA EDITING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; CELL LINE; CLONING, MOLECULAR; HUMANS; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; RATS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; RNA EDITING; RNA, MESSENGER; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TRANSFECTION;

EID: 0032840122     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00004-4     Document Type: Article

References (23)

1. Akbarian S, Smith MA, Jones EG (1995): Editing for an AMPA receptor subunit RNA in prefrontal cortex andstriatum in Alzheimer's disease, Huntington's diseaseand schizophrenia. Brain Res 699:297-304
2. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998): Effector-pathway-dependent relativeefficacy at serotonin type 2A and 2C receptors: Evidencefor agonist-directed trafficking of receptor stimulus.Mol Pharmacol 54:94-104
3. Berridge MJ, Downes PC, Hanley MR (1982): Lithium ampli-fies agonist-dependent phosphotidyinositol response in brain and salivary glands. Biochem J 206:587-595
4. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson R (1997): Regulation of seroto-nin-2C receptor G-protein coupling by RNA editing.Nature 387:303-308
5. Canton H, Emeson RB, Barker EL, Backstrom JR, Lu JT, Chang MS, Sanders-Bush E (1996): Identification, molecular cloning, and distribution of a short variant of the5-hydroxytryptamine 2C receptor produced by alternative splicing. Mol Pharmacol 50:799-807
6. Egan CT, Herrick-Davis K, Miller K, Glennon RA, and Teitler M (1998): Agonist activity of LSD and lisuride atcloned 5HT2Aand 5HT2Creceptors. Psychopharmacology 136:409-414
7. Fitzgerald LW, Patterson JP, Conklin DS, Horlick R, Largent BL (1998): Pharmacological and biochemical characterization of a recombinant human galanin GalR1 receptor:Agonist character of chimeric galanin peptides. J Pharmacol Exp Ther 287:448-456
8. Gomeza T, Kuhn K, Knopfel T, Bockaert J, Pin JP (1996): The second intracellular loop of metabotropic glutamatereceptor 1 cooperates with the other intracellular domainsto control coupling to G-proteins. J Biol Chem 271:2199-2205
9. Hartig PR (1997): Molecular biology and transductional characteristics of 5-HT receptors. In Gothert M, Baumgarten HG (eds), Handbook of Experimental Pharmacology vol.129, Serotoninergic Neurons and 5-HT Receptors in theCNS. Berlin, Springer Verlag, pp 175-212
10. Hodges P, Scott J (1992): Apolipoprotein B mRNA editing: A new tier for the control of gene expression. Trends Bio-chem Sci 17:77-81
11. Horlick RA, Sperle K, Breth LA, Reid CC, Shen ES, Robbinds AK, Cooke GM, Largent BL (1997): Rapid generation ofstable cell lines expressing corticotropin-releasing hormone receptor for drug discovery. Protein Expressionand Purification 9:301-308
12. Jonas P, Racca C, Sakmann B, Seeburg PH, Monyer H (1994): Differences in Ca2+ permeability of AMPA-type glutamate receptor channels in neocortical neurons causedby differential GluR-B subunit expression. Neuron 12:1281-1289
13. Lau PP, Cahill DJ, Zhu HJ, Chan L (1995): Ethanol modulates apolipoprotein B mRNA editing in the rat. J Lipid Res 36:2069-2078
14. Leff P (1995): The two-state model of receptor activation. Trend Pharmacol Sci 16:89-97
15. Lomeli H, Mosbacher J, Melcher T, Hoger T, Geiger JRP, Kuner T, Monyer H, Higuchi M, Bach A, Seeburg PH(1994): Control of kinetic properties of AMPA receptorchannels by nuclear RNA editing. Science 266:17091713
16. Paschen W, Schmitt J, Uto A (1996): RNA editing of glutamate receptor subunits GluR2, GluR5 and GluR6in transient cerebral ischemia in the rat. J Cereb BloodFlow Metab 16:548-556
17. Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J (1987): A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell50:831-840
18. Roth BL, Willins DL, Kristiansen K, Kroeze WK (1998): 5-hydroxytryptamine2-family receptors (5-hydroxytryp-tamine2A, 5-hydroxtryptamine2B, 5-hydroxytryptamine2C):Where structure meets function. Pharmacol Ther 79:231-257
19. Seeburg PH (1996): The role of RNA editing in controlling glutamate receptor channel properties. J Neurochem66:1-5
20. Simpson L, Emeson RB (1996): RNA editing. Annu Rev Neu-rosci 19:27-52
21. Smith HC, Gott JM, Hanson MR (1997): A guide to RNA editing. RNA 3:1105-1123
22. Sowden M, Hamm JK, Smith HC (1996): Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing. J Biol Chem 6:3011-3017
23. Wreggett KA, De Lean A (1984): The ternary complex model: Its properties and interactions with the D2 dopaminereceptor of the anterior pituitary. Mol Pharmacol26:214-227